Recent Quotes (30 days)

You have no recent quotes
chg | %

Microbix Biosystems Inc  

(Public, TSE:MBX)   Watch this stock  
Find more results for MBX
-0.005 (-1.67%)
Nov 21 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.29 - 0.31
52 week 0.20 - 0.40
Open 0.29
Vol / Avg. 64,000.00/31,795.00
Mkt cap 28.43M
P/E     -
Div/yield     -
EPS -0.02
Shares 96.37M
Beta -2.16
Inst. own     -
Dec 21, 2017
Q4 2017 Microbix Biosystems Inc Earnings Release (Estimated) Add to calendar

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 6.80% 7.86%
Operating margin 1.39% 1.56%
EBITD margin - 12.17%
Return on average assets 2.91% 3.07%
Return on average equity 4.81% 5.17%
Employees 20 -
CDP Score - -


265 Watline Ave
+1-905-3618910 (Phone)
+1-905-3618911 (Fax)

Website links


Microbix Biosystems Inc. is a life science company and manufacturer of viral and bacterial antigens and reagents for the diagnostics industry. The Company develops biological products and technologies. The Company operates in two segments: the development, manufacturing and distribution of cell-based products and technology, and the provision of facility, technical and production personnel for contract research and development. The Company's Virology Products (Virology) business manufactures and sells cell culture-based biological products. The Company's pipeline of technologies and products include Kinlytic, which is a thrombolytic drug with various applications, including the treatment of life-threatening blood clots, and LumiSort, which is a semen sexing technology for the livestock industries. It operates in three geographical areas, including North America, Europe and in other foreign countries. It owns and operates a Virology manufacturing facility at Mississauga, Ontario.

Officers and directors

William J. Gastle Executive Chairman of the Board
Cameron L. Groome President, Chief Executive Officer, Director
Jim Currie Chief Financial Officer
Age: 58
Vaughn C. Embro-Pantalony Executive Director
Peter M. Blecher Independent Director
Mark A. Cochran Independent Director
Martin A. Marino Independent Director
Joseph D. Renner Independent Director